Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Final Announcement 13th Symposium on Pharmacokinetics and Drug Metabolism Oligonucleotide-based therapeutics New challenges in evaluating pharmacokinetic, pharmacodynamic and safety properties March 16-17, 2015 Göteborg/Mölndal, Sweden Main sponsor: Cardiovascular and Metabolic Diseases R & D Mölndal Swedish Academy of Pharmaceutical Sciences The Section of Pharmacokinetics and Drug Metabolism within the Swedish Pharmaceutical Society is pleased to welcome you to the 13th Symposium on Pharmacokinetics and Drug Metabolism (previously known as the “Rosenön meeting”). The aim of the Symposium series is to highlight hot topics within the field. The scientific applications of oligonucleotide based drugs are rapidly increasing and have garnered tremendous interest over the past two decades. Oligonucleotide based drugs act at the level of messenger RNA (mRNA), either by direct targeting of mRNA or regulatory microRNA. Rather than modulating activity of specific proteins, these approaches lead to altered levels of target proteins and are independent of the structure of the protein, thus opening up completely new opportunities for drug interventions. However, oligonucleotide-based therapeutics carry specific challenges concerning drug delivery, organ- and cell uptake as well as pharmacokinetics and safety, which are the topics of this meeting. Who should attend? This multidisciplinary conference will be of interest to anyone engaged in drug discovery and development. Expected participants include academic and industrial scientists as well as regulatory assessors working on DMPK, toxicology, pharmacodynamics or pharmaceutics. We also encourage students to attend through a favorable student fee. The conference will cover the following areas: ✚✚ Introduction to oligonucleotide-based therapeutics ✚✚ Delivery, uptake and modeling of oligonucleotide drugs ✚✚ Regulation of ADME genes ✚✚ Safety aspects ✚✚ Regulatory aspects Organizing committee Tommy B. Andersson, AstraZeneca R&D, Sweden; Siv Jönsson, Uppsala University, Sweden; Gustav Ahlin, MPA, Sweden; Patrik J Andersson, AstraZeneca R&D, Sweden; Eva Lundborg, AstraZeneca R&D, Sweden; Shalini Andersson, AstraZeneca R&D, Sweden; Suzanne Iverson, AstraZeneca R&D, Sweden; Axel Ståhlbom, MPA, Sweden; Helena Sjöberg, AstraZeneca R&D, Sweden; Lilian WaltherJallow, Swedish Academy of Pharmaceutical Sciences, Sweden. Program For detailed program please visit www.lakemedelsakademin.se/oligo. Confirmed speakers Scott Henry, PhD, DABT, is Vice President of Non-Clinical Development at Isis Pharmaceuticals, CA, USA. Thomas Thum, MD, PhD, FESC, FAHA, is Professor and specialist in Internal Medicine and Cardiology at Institute for Molecular and Translational Therapeutic Strategies, Medizinische Hochschule Hannover, Germany. Robert Persson, PhD, is Senior Pharmacologist at Santaris Pharma A/S, Denmark. Sophie Callies (PharmD, PhD) is Principal Research Scientist in the global Pharmacokinetics/Pharmacodynamics and Pharmacometrics department at Eli Lilly, Paris, France. Monika Sundqvist, PhD, is a Preclinical and Translational PK & PKPD Scientist at AstraZeneca R&D Mölndal Sweden. Morten Lindow, PhD, is Associate director (informatics) at Santaris Pharma A/S and adjunct associate professor in bioinformatics at the University of Copenhagen, Denmark. Marino Zerial, PhD, is Director at the Max Planck Institute of Molecular Cell biology and Genetic and Honorary Professor at the Medical Faculty, University of Technology, Dresden, Germany. Bård Smedsrød, PhD, is Professor in Cell Biology and Head of Vascular Biology Research Group, at Department of Medical Biology, University of Tromsø, Norway and Founder and CSO of D’Liver. Magnus Ingelman-Sundberg, PhD, BScMed, is Professor, Section Head and Vice Chairman at Molecular Toxicology Department, Karolinska Institutet, Stockholm, Sweden. Patrik Andersson, PhD, is a Project Toxicologist of AstraZeneca and is currently spending a sabbatical period at Regulus Therapeutics and ISIS Pharmaceuticals, CA, USA. Camilla Svensson, PhD, is Non-Clinical Assessor of Biologics at the Department of Clinical Trials and Special Permissions, Medical Products Agency, Uppsala, Sweden. General Information Registration Registration is done at www.lakemedelsakademin.se. Before Febr 13 Beginning Febr 13 Industry 3000 SEK 3500 SEK Academy 2000 SEK 2500 SEK PhD Student/ 1000 SEK 1500 SEK Postdoc presenting a poster All prices excl. VAT The participation fee includes coffee lunch and dinner March 16-17. A number of rooms are pre-booked at Gothia Towers, www.gothiatowers.com on March 16-17, 2015. To book a room please use the folllowing code ”LÄK150315”. Rooms are available for booking until February 16, 2015. All prices are excl. VAT. Poster session The program includes a poster session, to which all delegates may apply. A number of accepted posters may be selected for oral presentation. Please submit your poster abstracts before February 16, 2015 by e-mail to jenny. [email protected]. Please register as soon as you have received information regarding acceptance of your abstract. Sponsors/Exhibitors We invite you to become one of the sponsors/exhibitors of the Rosenön Meeting 2014. To find information about sponsoring and exhibition please visit our web site www.lakemedelsakademin.se Venue The Rosenön Meeting takes place at hotel Gothia Towers in Göteborg on March 16 and at AstraZeneca in Mölndal on March 17. There will be a shuttle bus from the hotel to AstraZeneca in the morning of March 17. The official language of the meeting is English. Cancellation Policy For information about the cancellation policy, cancellation insurance and VAT, please see our home page www. lakemedelsakademin.se. Substitutes may however be made at any time. Kindly forward the name of the substitute to [email protected]. Please register at: www.lakemedelsakademin.se/oligo B Sverige Porto betalt Welcome to the 13th Symposium on Pharmacokinetics and Drug Metabolism – Oligonucleotide-based therapeutics Please register at: www.lakemedelsakademin.se/oligo Box 1136, 111 81 Stockholm, Sweden